|
Volumn 345, Issue , 2012, Pages
|
Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
RANIBIZUMAB;
DRUG INDUSTRY;
ECONOMICS;
EXUDATIVE MACULAR DEGENERATION;
HUMAN;
LEGAL ASPECT;
NATIONAL HEALTH SERVICE;
NOTE;
OFF LABEL DRUG USE;
UNITED KINGDOM;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
DRUG INDUSTRY;
ENGLAND;
HUMANS;
OFF-LABEL USE;
STATE MEDICINE;
WET MACULAR DEGENERATION;
|
EID: 84867063320
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.e5161 Document Type: Note |
Times cited : (2)
|
References (0)
|